相关实验视频

Updated: Sep 11, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

对于EGFR突变的高级非小细胞肺癌中使用 osimertinib 的真实临床经验

María Carmen Areses Manrique1, Luis León-Mateos2,3, Sofia Silva-Díaz4

  • 1Medical Oncology Department, University Clinical Hospital of Ourense, Calle Ramon Puga Noguerol, 54, 32005, Ourense, Spain. Maria.Carmen.Areses.Manrique@sergas.es.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|August 12, 2025
PubMed
概括

奥西默提尼布在西班牙现实环境中显示出作为EGFR突变非小细胞肺癌 (aNSCLC) 的第一线治疗方法的有效性和安全性. 在这些患者中,exon 19 删除预测了更好的结果.

关键词:
发生EGFR突变的原因皮表皮肤生长因子受体 (EGFR)在本地先进的先进.转移性 转移性非小细胞肺癌是非小细胞肺癌.奥西默蒂尼布 (Osimertinib) 是一种药物.现实世界的研究研究.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K